Cancers Ramp Up Overall mRNA Expression as They Progress

A technique for quantifying tumor mRNA production from messy tissue sample data uncovers an unexpected correlation between it and disease stage in 15 cancer types.

Written byDan Robitzski
| 4 min read
3D rendering of a scanning electron micrograph of pink malignant cancer cells against a black background
Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

The amount of mRNA expressed by a tumor seems to serve as a reliable indicator of disease progression, a new analysis of human tissue sample finds. The correlation, which researchers identified for 15 types of cancer, was enabled by a new statistical technique that helps make sense of massive sets of convoluted data.

Unlike research conducted on the homogenous tumors that cancer scientists can grow in a lab and use as experimental models, studying cancers that grow in humans can be a messy affair. Cancer cells, microbiota, and human immune cells can all exist in close proximity to one another, and researchers attempting to sequence the tumor cells typically choose between bulk sequencing, which yields difficult-to-interpret data, or single-cell sequencing, which quickly becomes costly in terms of both time and money. The new technique, however, can pull useful information out of bulk data generated from human cancer samples and provide ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here

Related Topics

Meet the Author

  • black and white image of young man in sunglasses with trees in background

    Dan is an award-winning journalist based in Los Angeles who joined The Scientist as a reporter and editor in 2021. Ironically, Dan’s undergraduate degree and brief career in neuroscience inspired him to write about research rather than conduct it, culminating in him earning a master’s degree in science journalism from New York University in 2017. In 2018, an Undark feature Dan and colleagues began at NYU on a questionable drug approval decision at the FDA won first place in the student category of the Association of Health Care Journalists' Awards for Excellence in Health Care Journalism. Now, Dan writes and edits stories on all aspects of the life sciences for the online news desk, and he oversees the “The Literature” and “Modus Operandi” sections of the monthly TS Digest and quarterly print magazine. Read more of his work at danrobitzski.com.

    View Full Profile
Share
July Digest 2025
July 2025, Issue 1

What Causes an Earworm?

Memory-enhancing neural networks may also drive involuntary musical loops in the brain.

View this Issue
Accelerating Recombinase Reprogramming with Machine Learning

Accelerating Recombinase Reprogramming with Machine Learning

Genome Modeling and Design: From the Molecular to Genome Scale

Genome Modeling and Design: From the Molecular to Genome Scale

Twist Bio 
Screening 3D Brain Cell Cultures for Drug Discovery

Screening 3D Brain Cell Cultures for Drug Discovery

DNA and pills, conceptual illustration of the relationship between genetics and therapeutic development

Multiplexing PCR Technologies for Biopharmaceutical Research

Thermo Fisher Logo

Products

waters-logo

Waters and BD's Biosciences & Diagnostic Solutions Business to Combine, Creating a Life Science and Diagnostics Leader Focused on Regulated, High-Volume Testing

zymo-research-logo

Zymo Research Partners with Harvard University to Bring the BioFestival to Cambridge, Empowering World-class Research

10x-genomics-logo

10x Genomics and A*STAR Genome Institute of Singapore Launch TISHUMAP Study to Advance AI-Driven Drug Target Discovery

The Scientist Placeholder Image

Sino Biological Sets New Industry Standard with ProPure Endotoxin-Free Proteins made in the USA